Redox state, oxidative stress and endothelial dysfunction in heart failure: The puzzle of nitrate-thiol interaction

Journal of Cardiovascular Medicine

Volumn 8, Issue 10, 2007, Pages 765-774

  Parodi, Oberdan ^a   De Maria, Renata ^a   Roubina, Elena ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Endothelial function; Heart failure; Nitrates; Oxidative stress; Redox state

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUTATHIONE; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE 2 NITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; METHIONINE; NITRATE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PEROXYNITRITE; PLACEBO; PRAZOSIN; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S NITROSOTHIOL; SUPEROXIDE; THIOL; THIOL GROUP;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; MEDICAL LITERATURE; NITRATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STIMULATION;

ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; NITRATES; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; SULFHYDRYL COMPOUNDS;

EID: 34748837884     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32801194d4     Document Type: Review

References (78)

1. Redfield MM. Heart failure - an epidemic of uncertain proportions. N Engl J Med 2002; 347:1442-1444.
2. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69:1596-1601.
3. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84:1589-1596.
4. Murad F. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA 1996; 276:1189-1192.
5. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med 2004; 351:2112-2114.
6. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-844.
7. Lopez Farre A, Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension 2001; 38:1400-1405.
8. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury, Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108:1912-1916.
9. Moat SJ, Bonham JR, Powers HJ. Role of aminothiols as a component of the plasma antioxidant system and relevance to homocysteine-mediated vascular disease. Clin Sci (Lond) 2001; 100:73-79.
10. Yardim-Akaydin S, Ozkan Y, Ozkan E, Torun M, Simsek B. The role of plasma thiol compounds and antioxidant vitamins in patients with cardiovascular diseases. Clin Chim Acta 2003; 338:99-105.
11. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 1998; 40:426-432.
12. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34:379-388.
13. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest 2001; 120:2035-2046.
14. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:1352-1356.
15. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14:1493-1498.
16. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106:3073-3078.
17. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41:2164-2171.
18. Oyama J, Shimokawa H, Momii H, Cheng X, Fukuyama N, Arai Y, et al. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest 1998; 101:2207-2214.
19. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115:500-508.
20. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113:1708-1714.
21. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990; 81:772-779.
22. Katz SD, Biasucci L, Sabba C, Strom JA, Jondeau G, Galvao M, et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992; 19:918-925.
23. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996; 93:210-214.
24. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998; 98:2709-2715.
25. Adams V, Linke A, Krankel N, Erbs S, Gielen S, Mobius-Winkler S, et al. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 2005; 111:555-562.
26. Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, et al. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 2005; 111:1763-1770.
27. Neglia D, Parodi O, Gallopin M, Sambuceti G, Giorgetti A, Pratali L, et al. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 1995; 92:796-804.
28. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002; 105:186-193.
29. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005; 25:1174-1179.
30. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26:65-69.
31. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103:799-805.
32. Joannides R, Bizet-Nafeh C, Costentin A, Iacob M, Derumeaux G, Cribier A, et al. Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure. Hypertension 2001; 38:1446-1450.
33. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105:2867-2871.
34. Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39:351-358.
35. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101:594-597.
36. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998; 95:9220-9225.
37. Jugdutt BI. Nitric oxide in heart failure: friend or foe. Heart Fail Rev 2002; 7:385-389.
38. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003; 93:388-398.
39. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30:535-560.
40. Radi R, Denicola A, Alvarez B, Ferrer-Sueta G, Rubbo H. The biological chemistry of peroxynitrite. In: Ignarro LJ, editor. Nitric oxide: biology and pathobiology. San Diego: Academic Press; 2000. pp. 57-82.
41. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003; 289:1675-1680.
42. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J, et al. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 1992; 298:438-445.
43. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992; 298:431-437.
44. Ischiropoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992; 298:446-451.
45. Datta B, Tufnell-Barrett T, Bleasdale RA, Jones CJ, Beeton I, Paul V, et al. Red blood cell nitric oxide as an endocrine vasoregulator: a potential role in congestive heart failure. Circulation 2004; 109:1339-1342.
46. Singel DJ, Stamler JS. Blood traffic control. Nature 2004; 430:297.
47. Godecke A. On the impact of NO-globin interactions in the cardiovascular system. Cardiovasc Res 2006; 69:309-317.
48. Romero N, Denicola A, Souza JM, Radi R. Diffusion of peroxynitrite in the presence of carbon dioxide. Arch Biochem Biophys 1999; 368:23-30.
49. Romero N, Radi R, Linares E, Augusto O, Detweiler CD, Mason RP, et al. Reaction of human hemoglobin with peroxynitrite. Isomerization to nitrate and secondary formation of protein radicals. J Biol Chem 2003; 278:44049-44057.
50. Anderson TJ, Meredith IT, Ganz P, Selwyn AP, Yeung AC. Nitric oxide and nitrovasodilators: similarities, differences and potential interactions. J Am Coll Cardiol 1994; 24:555-566.
51. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation 2002; 106:2404-2408.
52. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation 2002; 106:2510-2513.
53. Gori T, Fineschi M, Parker JD, Forconi S. Therapy with organic nitrates: newer ideas, more controversies. Ital Heart J 2005; 6:541-548.
54. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991; 84:2336-2345.
55. Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J 1985; 110 (Pt 2):216-224.
56. Diodati J, Theroux P, Latour JG, Lacoste L, Lam JY, Waters D. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol 1990; 66:683-688.
57. Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med 1980; 69:559-566.
58. Leier CV, Huss P, Magorien RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983; 67:817-822.
59. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552.
60. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.
61. Mehra A, Ostrzega E, Shotan A, Johnson JV, Elkayam U. Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. Am J Cardiol 1992; 70:1310-1314.
62. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992; 19:842-850.
63. Daiber A, Mulsch A, Hink U, Mollnau H, Warnholtz A, Oelze M, et al. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol 2005; 96:25i-36i.
64. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al., for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049-2057.
65. Gori T, Floras JS, Parker JD. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol 2002; 40:2000-2005.
66. Swedberg K, Cleland J, Dargie H, Drexler H, Follath K, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
67. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46:e1-e82.
68. Bitar F, Akhter MW, Khan S, Singh H, Elkayam U. Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States. Am J Cardiol 2004; 94:1465-1468.
69. Champion HC, Skaf MW, Hare JM. Role of nitric oxide in the pathophysiology of heart failure. Heart Fail Rev 2003; 8:35-46.
70. Dei Cas L, Nodari S, Metra M. Nitrates in chronic heart failure. Controversies in cardiology. Milan: Librex; 1998. pp. 253-256.
71. Sage PR, de la Lande IS, Stafford I, Bennett CL, Phillipov G, Stubberfield J, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000; 102:2810-2815.
72. Munzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000; 86:E7-E12.
73. Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol 2001; 37:505-509.
74. Boesgaard S, Poulsen HE, Aldershvile J, Loft S, Anderson ME, Meister A. Acute effects of nitroglycerin depend on both plasma and intracellular sulfhydryl compound levels in vivo. Effect of agents with different sulfhydryl-modulating properties. Circulation 1993; 87:547-553.
75. Boesgaard S, Aldershvile J, Poulsen HE, Loft S, Anderson ME, Meister A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 1994; 74:115-120.
76. Campolo J, De Maria R, Caruso R, Accinni R, Turazza F, Parolini M, et al. Blood glutathione as independent marker of lipid peroxidation in heart failure. Int J Cardiol 2006 [Epub ahead of print]
77. Parker JD. Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest 2004; 113:352-354.
78. Dejam A, Hunter CJ, Pelletier MM, Hsu LL, Machado RF, Shiva S, et al. Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood 2005; 106:734-739.